Novartis will spin off Alcon

Novartis International has decided to let go of its eye care business, Alcon, keeping only its portfolio of pharmaceutical products. In January, the group had announced a strategic review of the division, which is now completed. After examining alternative options including a public offering for Alcon, the management determined that ...

To continue reading this article subscribe now

Already an Eyewear Intelligence subscriber? Sign in here.

barrier_image_OIC

Become a member today for full access from just €6,70 a week!

Buying a membership today will give you:

  • Unlimited access to ewintelligence.com - all insight and analysis available online
  • Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
  • Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
  • Case studies and best practices on business challenges
  • Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
  • Access to over 11,500 articles and analyses in the archive
  • Personal library to save articles and track your key content
  • Powerful search and intuitive navigation

To continue reading this article register now.